See more : Surgutneftegas Public Joint Stock Company (SGGD.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Vitalibis, Inc. (VCBDQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vitalibis, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Golden Prospect Precious Metals Ltd. (GPM.L) Income Statement Analysis – Financial Results
- Tongcheng Travel Holdings Limited (TNGCF) Income Statement Analysis – Financial Results
- Imricor Medical Systems, Inc. (IMR.AX) Income Statement Analysis – Financial Results
- Oragenics, Inc. (OGEN) Income Statement Analysis – Financial Results
- Xinjiang Xuefeng Sci-Tech(Group)Co.,Ltd (603227.SS) Income Statement Analysis – Financial Results
Vitalibis, Inc. (VCBDQ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.vitalibis.com
About Vitalibis, Inc.
Vitalibis, Inc. operates as a technology-based formulator of phytocannabinoid rich hemp products with cannabidiol, along with personal care and nutritional products. The company markets and sells consumer products under the Vitalibis brand. It also sells water soluble phytocannabinoid rich hemp powder. The company was formerly known as Sheng Ying Entertainment Corp. and changed its name to Vitalibis, Inc. in February 2018. Vitalibis, Inc. was founded in 2014 and is based in Las Vegas, Nevada.
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 303.20K | 51.33K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 162.51K | 23.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 140.69K | 28.33K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 46.40% | 55.19% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.02M | 2.26M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 2.10M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 2.26M | 102.87K | 61.00K | 63.00K |
| Other Expenses | 0.00 | 0.00 | -39.00 | 0.00 | 0.00 |
| Operating Expenses | 6.02M | 2.26M | 102.87K | 61.00K | 63.00K |
| Cost & Expenses | 6.19M | 2.28M | 102.87K | 61.00K | 63.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.05M | 700.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 58.73K | 27.07K | 52.52K | -122.00K | -126.00K |
| EBITDA | -5.82M | -2.20M | -102.87K | -61.00K | -63.00K |
| EBITDA Ratio | -1,921.09% | -4,287.56% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.88M | -2.23M | -102.87K | 61.00K | 63.00K |
| Operating Income Ratio | -1,940.46% | -4,340.30% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -962.54K | -700.00 | -39.00 | -122.00K | -126.00K |
| Income Before Tax | -6.85M | -2.23M | -102.90K | -61.00K | -63.00K |
| Income Before Tax Ratio | -2,257.92% | -4,341.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -6.85M | -2.23M | -102.90K | -61.00K | -63.00K |
| Net Income Ratio | -2,257.92% | -4,341.66% | 0.00% | 0.00% | 0.00% |
| EPS | -0.22 | -0.08 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.22 | -0.08 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 30.96M | 28.64M | 24.40M | 56.59M | 22.64M |
| Weighted Avg Shares Out (Dil) | 30.96M | 28.64M | 24.40M | 56.59M | 22.64M |
Source: https://incomestatements.info
Category: Stock Reports